title: Immune thrombocytopenia induced by fludarabine successfully treated with rituximab.
authors.affiliation: Department of Hematology. Hospital Lluis Alcanyis. Cta. Xativa-Silla, Spain.
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Fernandez
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Llopis
authors.forename: Emilio
authors.initials: E
authors.lastname: Pastor
authors.forename: Esperanza
authors.initials: E
authors.lastname: Real
authors.forename: Enric
authors.initials: E
authors.lastname: Grau
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy; D000069283:Rituximab; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology*; D016896:Treatment Outcome; D014740:Vidarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014740:Vidarabine; C024352:fludarabine